MCFADYEN, M.C.E., MELVIN, W.T. and MURRAY, G.I. 1997. *Cytochrome P450 in human brain tumours*. Presented at the 1997 Joint winter meeting of the British Association for Cancer Research, the Association of Cancer Physicians and the Royal Society of Medicine (Oncology Section), 27-28 November 1997, London, UK.

Cytochrome P450 in human brain tumours.

MCFADYEN, M.C.E., MELVIN, W.T. and MURRAY, G.I.

1997

The extended abstract in this file has been published with the following citation: MCFADYEN, M.C.E., MELVIN, W.T. and MURRAY, G.I. 1998. Cytochrome P450 in human brain tumours. British journal of cancer [online], 78(2): cancer cure: drugs, genes or surgery? Abstracts from the 1997 Joint winter meeting of the British Association for Cancer Research, the Association of Cancer Physicians and the Royal Society of Medicine (Oncology Section), 27-28 November 1997, London, UK, page 153. Available from: https://doi.org/10.1038/bjc.1998.457



This document was downloaded from https://openair.rgu.ac.uk



of xenobiotics, including carcinogens and anti-cancer drugs. This family of enzymes are thus involved in tumour development and the response of established tumours to anti-cancer drugs. In this study, we have investigated the presence and cellular localization of individual families of P450 in normal human brain and primary brain tumours. Sections of formalin-fixed wax-embedded normal and tumour brain were used and the immunoreactivity of individual P450s was identified using light microscopic immunohistochemistry. In normal brain, immunoreactivity was observed for CYP1A, CYP2C, CYP2E1 and CYP3A, while there was no immunoreactivity for CYP1B1. Immunoreactivity in normal brain was mainly localized to neuronal cell bodies. All the tumours studied were astrocytomas, and CYP1A was present in 96% of tumours, while CYP1B1 was present in 87% of tumours. There was no significant immunoreactivity for CYP2C and CYP2E1. CYP3A immunoreactivity was identified in 43% of tumours. In all cases, positive immunoreactivity for each P450 was identified in tumour cells and, generally, in positively staining cells, the immunoreactivity was strong. The presence of individual forms of the CYP1 and CYP3A families in brain tumours provides further evidence for the expression of specific forms of P450 in malignant tumours. Individual forms of P450 in brain tumours could be important therapeutically for the development of anti-cancer drugs that are activated by those forms of P450.

This research was supported by grants from The Association for International Cancer Research and Tenovus-Scotland.

Cytochrome P450 in human brain tumours

MCE McFadyen¹, WT Melvin² and GI Murray¹

¹Department of Pathology, ²Department of Molecular and Cell Biology, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK

The cytochromes P450 (P450) are a large group of constitutive and inducible oxidative enzymes with a major role in the metabolism